Filed by Elscint Ltd. Pursuant to Rule 425
                                      Under the Securities Act of 1933
                                      And deemed filed pursuant to Rule 14a-12
                                      Under the Securities Exchange Act of 1934
                                      Subject Company: Elscint Ltd.
                                      Commission File No.: 001-08781


Press Release                                               Source: Elscint Ltd.

                ELSCINT LIMITED ANNOUNCES RESULTS OF ITS SPECIAL
                                 GENERAL MEETING

        Tel Aviv, Israel - October 27, 2005 - Elscint Ltd. (NYSE: ELT)
("Elscint"), announced today that at a special meeting of its shareholders held
today Elscint's shareholders approved by approximately 96.52% majority the
agreement and plan of merger between Elscint and Elbit Medical Imaging Ltd.
("EMI"), the indirect controlling shareholder of Elscint, dated August 21, 2005
(the "Merger").

        Under the Merger, each 1 ordinary share of Elscint (other than Elscint
ordinary shares held by EMI and Elscint) will be exchanged for 0.53 ordinary
shares of EMI. Following the closing of the Merger Elscint will become a
wholly-owned subsidiary of EMI. [For additional details regarding the Merger,
see the registration statement published by EMI on September 27, 2005.]

        The closing of the Merger is subject to the fulfillment of additional
conditions, which have not yet been obtained, including, among others, the
consent of various financing institution to the Merger and the receipt of a
final court order approving the Merger.


About Elscint Limited

Elscint Limited is engaged in two principal businesses: Hotel development and
leisure, and investments in bio-technology companies. Elscint has interests in
hotels in Western Europe, in hotel development projects, principally in Western
and Central Europe, and in the commercial and entertainment center at the Marina
in Herzlia, Israel. In the bio-technology field, Elscint invests in high
potential start-up companies, and provides business guidance and professional
advice to such companies for the development of business plans, research and
development and marketing programs. More information regarding the Company is
available at: http://www.elscint.net

       This release contains certain forward-looking statements, which involve
known and unknown risks, uncertainties or other factors not under the Company's
control. The Company does not undertake to update the information set forth in
this release.



For Further Information:

Company Contact                                   Investor Contact

Abraham (Rami) Goren                              Kathy Price
Elscint, Ltd.                                     The Anne McBride Company
+972-3-608-6020                                   +212-983-1702, x212
argoren@elscint.net                               kprice@annemcbride.com
- -------------------                               ----------------------